ESPR Q1 2020 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2M-98.7% YoY

Gross Profit

$2M98.3% margin

Operating Income

-$74M-4046.0% margin

Net Income

-$78M-4252.7% margin

EPS (Diluted)

$-2.84

QoQ Revenue Growth

+87.4%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$70M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$180M

Total Liabilities

$230M

Stockholders' Equity

-$50M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$145M	-98.7%
Gross Profit	$2M	$99M	-98.2%
Operating Income	-$74M	$87M	-185.6%
Net Income	-$78M	$87M	-189.6%

Revenue Segments

Collaboration Revenue

$982,00053%

Product

$858,00047%